Flesinoxan

Flesinoxan

Flesinoxan is a quinuclidinyl benzamide derivative that acts as a potent and selective 5-HT1A receptor agonist. It was originally developed by Pfizer in the 1980s for the treatment of hypertension and migraine, but was later abandoned and is now used primarily in scientific research.

History

Flesinoxan was first synthesized by Pfizer in the 1980s as part of a research program aimed at developing new treatments for hypertension and migraine. Early clinical trials showed promising results, but the drug was ultimately not brought to market for these indications. Today, it is used primarily in scientific research, particularly in studies investigating the role of the 5-HT1A receptor in various physiological and pathological processes.

Pharmacology

Flesinoxan is a potent and selective 5-HT1A receptor agonist. It binds to the 5-HT1A receptor with high affinity, and activates the receptor to produce its biological effects. The 5-HT1A receptor is a type of serotonin receptor that is widely distributed in the brain and plays a key role in the regulation of mood, anxiety, and the stress response.

Clinical Use

While Flesinoxan was originally developed for the treatment of hypertension and migraine, it is now used primarily in scientific research. It is often used as a tool to investigate the role of the 5-HT1A receptor in various physiological and pathological processes, including mood disorders, anxiety disorders, and the stress response.

See Also

• 5-HT1A receptor
• Serotonin receptor
• Pfizer

References

‎